NASDAQ NMS - GLOBAL MARKET · LXEO
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
Lexeo Therapeutics Inc

Lexeo Therapeutics Inc

Biotechnology
$4.98
Card
Relationship Map

Veridion Score

BETALOW CONF · 5/6 factorsMethodology
Sentiment absence reason unknown
LXEO
Lexeo Therapeutics Inc
Mon Aug 17 · last completed session · Pre-market · regular session opens 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

59/ 100
Veridion Score
NEUTRAL · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 5/6 factors with data · Mon Aug 17 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Score not reportedVeridion does not publish a score-history trend for LXEO until the ticker has a real scored snapshot. No trend is implied for this page.Review methodology
AI Analysis
Sovereign

Why is LXEO moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading LXEO catalysts
About Lexeo Therapeutics Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2023
Employees
59
Country
US

Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$4.98
Last session
Day high
$4.98
Last session
Day low
$4.98
Last session
Previous close
$4.98
52W high
$10.63
-53.15% from high
52W low
$4.13
13% of range
Market cap
$397.1M
EPS
$-1.4800
Beta
1.83
Shares out
82M
Avg volume
993.8K
VWAP
$4.98
Last session
Price history computed in-house
1W
+4.18%
1M
+6.18%
3M
-2.73%
1Y
+1.22%
YTD
-49.85%
SMA 50 $4.64 · above
SMA 200 $6.68 · below
52W position 13%

LXEO overview

Veridion Score
Not reported
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around LXEO.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading LXEO Form 4 filings
Public disclosures

Congress activity in LXEO

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for LXEO in the cached public ledger.

Federal contracts

LXEO contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for LXEO in this window.
Lobbying spend

LXEO lobbying filings, year to date.

Registered lobbying filings matched to Lexeo Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for LXEO in this window.
Loading news for LXEO
Analyst ratings
Sovereign unlock shows live analyst consensus for LXEO.
Options
Sovereign unlock shows live options positioning for LXEO.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.